I know that Tom is definitely going to disagree with me on this one as it is a company that he has been keen on for a long time, but I’m really struggling to see what all the fuss is about with OptiBiotix Health (OPTI), when you look at the actual news flow that the company has announced..
A “TR-1” (shareholding) announcement on the holding of Optibiotix Health (OPTI) in SkinBioTherapeutics (SBTX). So what’s this news?
I discussed Optibiotix (OPTI) selling 3% of Skinbiotherapeutics (SBTX) in bearcast yesterday HERE. As a result of the disposal I have cut my target for Optibiotix from 82p to 78p but the cash position is enhanced so it is de-risked. But I am pissed off, not least with the way broker Cenkos behaved. I think Cenkos should be fired. Here is how the conversation between Cenkos and O’Hara went ( I imagine):
7p was the wrong price for shares in Optibiotix (OPTI). Anyone who has watched last Thursday’s video interview I did with Steve O’Hara HERE will agree. But what about 37.6p where they are now valuing the company at £33 million? Is that crazy? I write as a shareholder for more than 10 years!
OptiBiotix Health (OPTI) has issued a “SweetBiotix” update announcement, including significant progress in commercial scale production development with final product taste tested and accepted by its US partner. However, what about a more than 60% share price rise in response and now even more?
I own the shares and I think that even without any deal the shares will multibag, as I explained in a podcast after the piss poor results HERE. And I would argue that the odds of Optibiotix (OPTI) securing a transformational deal with Coca Cola to put the “sweet” into diet coke are long. But I can reveal that they are talking and with good reason.
I am told by at least one reader that a 1 million shares sale in Skinbiotherapeutics (SBTX) MUST be Optibiotix (OPTI). The bulletin boards are full of ill-informed speculation. I am in a good mood today because West Ham are Massive so I shall not label such folks morons. Okay I will. They are morons. I have swapped emails with both Steve O’Hara of Optibiotix and Stuart Ashman of Skins.
The slideshow below is that given by Optibiotix (OPTI) in a capital markets day yesterday. I have a few takeaways.
OptiBiotix Health (OPTI) has announced that a director and CEO of its operating business René Kamminga is to “leave the business on 28 February 2023 to pursue other opportunities”, with OptiBiotix CEO Stephen O'Hara to resume the role as CEO of the operating business and to “lead a minor restructuring of the business, with further announcements to be made in due course”. So what’s really going on here?
OptiBiotix Health (OPTI) CEO Steve O'Hara states that he is “pleased with the interest shown from new and existing shareholders in this fundraise which will support further company growth”. We weren’t pleased and managed to interrupt his holiday in the West Indies to get some answers.
On developer of “compounds to tackle obesity, cardiovascular disease and diabetes”, OptiBiotix Health (OPTI) we’ve previously noted ‘some delays in delivery but a sales recovery Buy’ – including with “product launches by Apollo Pharmacies in India and restocking by some partners with sales normalising… as in previous years, there was no contribution in this period from licence or royalty payments which tend to be received in the second half”. We’ve since again spoken to CEO Steve O'Hara.
OptiBiotix Health (OPTI), a developer of “compounds to tackle obesity, cardiovascular disease and diabetes”, has recently provided an update presentation on its commercial strategy and future plans. At a current 19p, the shares are at least up from 16.5p lows last month but remain well down from above 30p as recently as August and 46p at the start of this year and we’ve spoken to CEO Steve O'Hara.
OptiBiotix Health (OPTI) has announced the opening of an online shop on Tmall.com for its Go-Figure products and that it has launched GoFigure shakes containing patented weight management aid SlimBiome on Tmall China. What of this and of a share price edging up to 19p to buy?
OptiBiotix Health (OPTI) has announced Nahdi Medical Co has received approval from the Saudi Food and Drug Authority for GoFigure shakes and bars and that it has received the first purchase order from Nahdi.
Previously writing on OptiBiotix Health (OPTI), earlier this month we noted prior delays in delivery from larger deals but that orders are already coming through and being booked as second half sales. Now some clear evidence of this with an announcement that the company’s GoFigure meal replacement shakes and powdered beverage shots have now been officially launched by India's Apollo Hospitals & Pharmacies.
